Bayesian Multiple Testing for Suicide Risk in Pharmacoepidemiology: Leveraging Co-Prescription Patterns

TL;DR

This paper introduces a Bayesian framework that leverages co-prescription patterns to improve detection of medication-related suicide risks in large-scale pharmacoepidemiological data, enhancing signal detection and hypothesis generation.

Contribution

It develops a structured Bayesian spike-and-slab model that incorporates co-prescription networks for better rare-event detection in pharmacovigilance studies.

Findings

Confirmed known harmful and protective drug signals.

Identified new potential risk and protective associations.

Showed how co-prescription metrics influence effect estimates.

Abstract

Suicide is the tenth leading cause of death in the United States, yet evidence on medication-related risk or protection remains limited. Most post-marketing studies examine one drug class at a time or rely on empirical-Bayes shrinkage with conservative multiplicity corrections, sacrificing power to detect clinically meaningful signals. We introduce a unified Bayesian spike-and-slab framework that advances both applied suicide research and statistical methodology. Substantively, we screen 922 prescription drugs across 150 million patients in U.S. commercial claims (2003 to 2014), leveraging real-world co-prescription patterns to inform a covariance prior that adaptively borrows strength across pharmacologically related agents. Statistically, the model couples this structured prior with Bayesian false-discovery-rate control, illustrating how network-guided variable selection can improve rare-event surveillance in high dimensions. Relative to the seminal empirical-Bayes analysis of Gibbons et al. (2019), our approach reconfirms the key harmful (e.g., alprazolam, hydrocodone) and protective (e.g., mirtazapine, folic acid) signals while revealing additional associations, such as a high-risk opioid combination and several folate-linked agents with potential preventive benefit that had been overlooked. A focused re-analysis of 18 antidepressants shows how alternative co-prescription metrics modulate effect estimates, shedding light on competitive versus complementary prescribing. These findings generate actionable hypotheses for clinicians and regulators and showcase the value of structured Bayesian modeling in pharmacovigilance.